We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

14 hedge funds and large institutions have $6.37M invested in Akari Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

279% more capital invested

Capital invested by funds: $1.68M → $6.37M (+$4.69M)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more funds holding

Funds holding: 14 → 14 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$4.42M
2
SM
Sabby Management
Florida
+$4.22M
3
LPL Financial
LPL Financial
California
+$41.2K
4
OFW
Omnia Family Wealth
Florida
+$24.7K
5
Millennium Management
Millennium Management
New York
+$23.9K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$33K
2
Citadel Advisors
Citadel Advisors
Florida
-$15K
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$12K
4
Renaissance Technologies
Renaissance Technologies
New York
-$5.77K
5
UBS Group
UBS Group
Switzerland
-$2.47K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.7M +$4.42M +5,363 New
SM
2
Sabby Management
Florida
$2.58M +$4.22M +5,129 New
OFW
3
Omnia Family Wealth
Florida
$493K +$24.7K +30 +3%
NMC
4
NEA Management Company
Maryland
$285K – – –
HP
5
Hikari Power
Japan
$82K – – –
LPL Financial
6
LPL Financial
California
$77K +$41.2K +50 +48%
BMCM
7
Bryn Mawr Capital Management
Pennsylvania
$63K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$25K -$5.77K -7 -12%
Millennium Management
9
Millennium Management
New York
$24K +$23.9K +29 +161%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$19K – – –
HTC
11
Haverford Trust Company
Pennsylvania
$13K +$20.6K +25 New
Bank of America
12
Bank of America
North Carolina
$2K – – –
TC
13
Truvestments Capital
Florida
$1K – – –
TSS
14
Two Sigma Securities
New York
– -$33K -41 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$15K -19 Closed
PNC Financial Services Group
16
PNC Financial Services Group
Pennsylvania
– -$12K -14 Closed
UBS Group
17
UBS Group
Switzerland
– -$2.47K -3 -75%

AKTX Hedge Fund Activity: Q3 2022 in Review

14 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2022, worth a combined $6.37M — up 279% from $1.68M a quarter earlier.

Fund positioning in AKTX was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $4.42M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $33K sold.

  • 14 institutional investors held Akari Therapeutics (AKTX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $6.37M of Akari Therapeutics stock for Q3 2022, up 279% quarter-over-quarter.
  • 3 funds opened new Akari Therapeutics positions in Q3 2022 and 3 closed out, a net change of 0 holders.
  • The largest Akari Therapeutics buyer in Q3 2022 was Armistice Capital, an estimated $4.42M added.
  • The largest Akari Therapeutics seller in Q3 2022 was Two Sigma Securities, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2022.